Acorda Can't Add $66M To Award In Ampyra Royalty Fight
By Caroline Simson · July 15, 2026, 9:42 PM EDT
The Second Circuit on Wednesday refused to alter an arbitral award issued to Acorda Therapeutics to include nearly $66 million beyond the $16.6 million it won in a multiple sclerosis drug...
To view the full article, register now.